OTCMKTS:LZAGY Lonza Group (LZAGY) Stock Price, News & Analysis $58.89 +0.21 (+0.36%) As of 01/3/2025 05:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Lonza Group Stock (OTCMKTS:LZAGY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lonza Group alerts:Sign Up Key Stats Today's Range$58.53▼$58.9650-Day Range$57.28▼$63.5652-Week Range$40.14▼$67.00Volume47,769 shsAverage Volume38,884 shsMarket Capitalization$42.53 billionP/E RatioN/ADividend Yield0.32%Price TargetN/AConsensus RatingStrong Buy Company OverviewLonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.Read More… Lonza Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks26th Percentile Overall ScoreLZAGY MarketRank™: Lonza Group scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lonza Group.Read more about Lonza Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth15.19% Earnings GrowthEarnings for Lonza Group are expected to grow by 15.19% in the coming year, from $1.58 to $1.82 per share.Price to Earnings Growth RatioLonza Group has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLonza Group has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Lonza Group have been sold short.Short Interest Ratio / Days to CoverLonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lonza Group has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldLonza Group has a dividend yield of 0.33%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLonza Group does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Lonza Group will have a dividend payout ratio of 10.44% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.Read more about Lonza Group's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Lonza Group have been sold short.Short Interest Ratio / Days to CoverLonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lonza Group has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentLonza Group has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.MarketBeat FollowsOnly 30 people have added Lonza Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lonza Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of Lonza Group is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of Lonza Group is held by institutions.Read more about Lonza Group's insider trading history. Receive LZAGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter. Email Address LZAGY Stock News HeadlinesLonza seeks deals as it exits health and ingredients to focus on contract developmentDecember 13, 2024 | reuters.comLonza Streamlines Business With Capsules Unit ExitDecember 12, 2024 | msn.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. January 6, 2025 | Crypto 101 Media (Ad)Lonza to exit capsules and health ingredients business, focus on contract developmentDecember 12, 2024 | msn.comLonza Group Ltd (LONN) Receives a Buy from BarclaysNovember 29, 2024 | markets.businessinsider.comLonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing SuitesNovember 13, 2024 | markets.businessinsider.comLonza Group AG (LZAGY): Among UBS’ Top Tech Based Disruptive Stocks For 2030October 30, 2024 | insidermonkey.comLonza Group Ltd (LONN) Gets a Buy from Kepler CapitalOctober 26, 2024 | markets.businessinsider.comSee More Headlines LZAGY Stock Analysis - Frequently Asked Questions How have LZAGY shares performed this year? Lonza Group's stock was trading at $58.78 on January 1st, 2025. Since then, LZAGY stock has increased by 0.2% and is now trading at $58.89. View the best growth stocks for 2025 here. Does Lonza Group have any subsidiaries? Lonza Group subsidiaries include Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and others. How do I buy shares of Lonza Group? Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today1/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Tobacco products Sub-IndustryN/A Current SymbolOTCMKTS:LZAGY CUSIPN/A CIK1446711 Webwww.lonza.com Phone(161) 316-8111Fax41-61-316-9111Employees17,834Year Founded1897Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio37.27 P/E Growth2.78Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.48 billion Price / Sales5.69 Cash Flow$2.05 per share Price / Cash Flow28.79 Book Value$14.23 per share Price / Book4.14Miscellaneous Outstanding Shares722,262,000Free Float721,756,000Market Cap$42.53 billion OptionableNot Optionable Beta0.97 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:LZAGY) was last updated on 1/6/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia second company to cross $3.5 trillion. It’s just the startNvidia has moved on to the next frontier of AI it intends to dominate. And we believe the three companies p...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lonza Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Lonza Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.